Codexis Announces First Revenue-Generating Contract for ECO Synthesis™ Manufacturing Services
Codexis (NASDAQ: CDXS) has secured its first revenue-generating contract for manufacturing siRNA material using their ECO Synthesis™ Innovation Lab. The company has successfully developed and validated the first generation of core ECO Synthesis™ enzymes, meeting pre-specified criteria for industrial-scale production.
This milestone follows their previous achievements in dsRNA ligation offerings. The company plans to demonstrate process parameters that are comparable to or potentially superior to traditional chemical methods at upcoming scientific meetings.
Codexis (NASDAQ: CDXS) ha ottenuto il suo primo contratto generatore di entrate per la produzione di materiale siRNA utilizzando il loro ECO Synthesis™ Innovation Lab. L'azienda ha sviluppato e convalidato con successo la prima generazione di enzimi ECO Synthesis™ fondamentali, soddisfacendo i criteri predefiniti per la produzione su scala industriale.
Questo traguardo segue i loro successi precedenti nelle offerte di legatura dsRNA. L'azienda prevede di dimostrare parametri di processo che sono comparabili o potenzialmente superiori ai metodi chimici tradizionali in occasione di prossimi incontri scientifici.
Codexis (NASDAQ: CDXS) ha asegurado su primer contrato generador de ingresos para la fabricación de material de siRNA utilizando su ECO Synthesis™ Innovation Lab. La empresa ha desarrollado y validado con éxito la primera generación de enzimas ECO Synthesis™ centrales, cumpliendo con los criterios predefinidos para la producción a escala industrial.
Este hito sigue a sus logros anteriores en las ofertas de ligadura de dsRNA. La empresa planea demostrar parámetros de proceso que son comparables o potencialmente superiores a los métodos químicos tradicionales en las próximas reuniones científicas.
Codexis (NASDAQ: CDXS)는 ECO Synthesis™ Innovation Lab을 사용하여 siRNA 물질 제조를 위한 첫 번째 수익 창출 계약을 체결했습니다. 이 회사는 산업 규모 생산을 위한 사전 지정된 기준을 충족하며 첫 번째 세대의 핵심 ECO Synthesis™ 효소를 성공적으로 개발하고 검증했습니다.
이 이정표는 dsRNA 연결 제공에서의 이전 성과에 이어진 것입니다. 이 회사는 다가오는 과학 회의에서 전통적인 화학 방법과 비교할 수 있거나 잠재적으로 우수한 공정 매개 변수를 시연할 계획입니다.
Codexis (NASDAQ: CDXS) a obtenu son premier contrat générateur de revenus pour la fabrication de matériel siRNA en utilisant leur ECO Synthesis™ Innovation Lab. L'entreprise a développé et validé avec succès la première génération d'enzymes ECO Synthesis™ essentielles, répondant aux critères préétablis pour la production à l'échelle industrielle.
Cette étape fait suite à ses réalisations précédentes dans les offres de ligature de dsRNA. L'entreprise prévoit de démontrer des paramètres de processus comparables ou potentiellement supérieurs aux méthodes chimiques traditionnelles lors des prochaines réunions scientifiques.
Codexis (NASDAQ: CDXS) hat seinen ersten umsatzgenerierenden Vertrag zur Herstellung von siRNA-Material unter Verwendung ihres ECO Synthesis™ Innovation Lab gesichert. Das Unternehmen hat erfolgreich die erste Generation von ECO Synthesis™-Enzymen entwickelt und validiert, die die vorab festgelegten Kriterien für die industrielle Produktion erfüllen.
Dieser Meilenstein folgt auf ihre vorherigen Erfolge im Bereich der dsRNA-Ligation. Das Unternehmen plant, Prozessparameter zu demonstrieren, die mit traditionellen chemischen Methoden vergleichbar oder potenziell überlegen sind, bei bevorstehenden wissenschaftlichen Tagungen.
- First revenue-generating contract secured for ECO Synthesis™ manufacturing services
- Successful development of industrial-scale capable enzymes
- Expansion of product portfolio from dsRNA to siRNA manufacturing
- None.
Represents first project to enter the ECO Synthesis™ Innovation Lab
Core enzymes for ECO Synthesis™ technology have transitioned from research into development and scale-up as the first step in securing the raw materials supply chain
REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced its first revenue-generating contract to manufacture siRNA material in its ECO Synthesis™ Innovation Lab.
Codexis has also successfully completed development of the first generation of its core ECO Synthesis™ enzymes, having met the pre-specified criteria to support scaling to industrial capacity.
“We are excited to sign this first revenue-generating contract for ECO Synthesis™, which builds on our previous success with our dsRNA ligation offering,” said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. “I’m also delighted that our research organization has successfully built a suite of enzymes capable of driving the ECO Synthesis™ platform at industrial scale. We look forward to demonstrating process parameters comparable with or better than chemical methods at upcoming scientific meetings.”
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “suggest,” “target,” “on track,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management, including but not limited to statements regarding the potential of the ECO Synthesis™ platform, and it providing an opportunity for Codexis to efficiently capture meaningful market share; expectations regarding Codexis meeting its technical and commercial milestones regarding the ECO Synthesis™ platform; and expectations regarding the potential of and future demand for RNAi therapeutics, and whether Codexis will be able to capitalize on such demand. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis’ dependence on its licensees and collaborators; if any of its collaborators terminate their development programs under their respective license agreements with Codexis; Codexis may need additional capital in the future in order to expand its business; if Codexis is unable to successfully develop and commercialize new technology such as its ECO Synthesis™ platform and its dsRNA ligase; Codexis dependence on a limited number of products and customers, and potential adverse effects to Codexis’ business if its customers’ products are not received well in the markets; if competitors and potential competitors who have greater resources and experience than Codexis develop products and technologies that make Codexis’ products and technologies obsolete; if Codexis is unable to accurately forecast financial and operational performance; and market and economic conditions may negatively impact Codexis business, financial condition and share price. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 27, 2025 and in Codexis’ Quarterly Report on Form 10-Q filed with the SEC on October 31, 2024, including under the caption “Risk Factors,” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
FAQ
What is the significance of Codexis (CDXS) first ECO Synthesis contract?
How far has Codexis (CDXS) progressed with ECO Synthesis enzyme development?
What are the expected performance metrics for Codexis ECO Synthesis technology?
How does the ECO Synthesis contract build on Codexis previous offerings?
